A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
NCT ID: NCT02503189
Last Updated: 2017-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
NCT02503163
An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
NCT02503176
A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
NCT01890941
A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
NCT01692145
A Study of KCT-0809 in Patients With Dry Eye Syndromes
NCT01211951
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
KCT-0809
KCT-0809 ophthalmic solution
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KCT-0809 ophthalmic solution
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Corneal and conjunctival damage
Exclusion Criteria
* Punctal plugs or surgery for occlusion of the lacrimal puncta
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kissei Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tokyo and Other Japanese City, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KCT1301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.